Ontology highlight
ABSTRACT: Background
Carnitine palmitoyltransferase-1 (CPT1) is a rate-limiting step of mitochondrial β-oxidation by controlling the mitochondrial uptake of long-chain acyl-CoAs. The muscle isoform, CPT1b, is the predominant isoform expressed in the heart. It has been suggested that inhibiting CPT1 activity by specific CPT1 inhibitors exerts protective effects against cardiac hypertrophy and heart failure. However, clinical and animal studies have shown mixed results, thereby creating concerns about the safety of this class of drugs. Preclinical studies using genetically modified animal models should provide a better understanding of targeting CPT1 to evaluate it as a safe and effective therapeutic approach.Methods and results
Heterozygous CPT1b knockout (CPT1b(+/-)) mice were subjec
SUBMITTER: He L
PROVIDER: S-EPMC3484985 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature